Evidence map›Paper›PMID 42733609›Full record

ArticleClinical ophthalmology (Auckland, N.Z.)2026

Patient-Reported Quality of Life and Treatment Experiences Among Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Aflibercept in Colombia: A Qualitative Study.

Maria Adelaida Piedrahita, Wanderley Augusto Arias-Ortiz, Claudia Patricia Acosta Cadavid, Eduardo Cadena Galvis, Fernando Yaacov Peña

Abstract read
In one paragraph

Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Maria Adelaida PiedrahitaDepartment of Ophthalmology, Faculty of Medicine, Universidad El Bosque, Bogotá, Colombia.
Wanderley Augusto Arias-OrtizFaculty of Medicine, Universidad El Bosque, Bogotá, Colombia.ORCID 0000-0002-6606-4627
Claudia Patricia Acosta CadavidInstituto Nacional de Investigación en Oftalmología, Medellín, Colombia.
Eduardo Cadena GalvisDepartment of Ophthalmology, Faculty of Medicine, Universidad El Bosque, Bogotá, Colombia.
Fernando Yaacov PeñaDepartment of Ophthalmology, Faculty of Medicine, Universidad El Bosque, Bogotá, Colombia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To explore the experiences and perceptions of patients with neovascular age-related macular degeneration (AMD) receiving anti-VEGF therapy and understand how treatment influences their quality of life. Patients and Methods: A qualitative study informed by a phenomenological perspective and employing a hybrid deductive-inductive thematic analysis was conducted at an ophthalmologic center in Medellín, Colombia. Fourteen patients with confirmed AMD undergoing intravitreal aflibercept treatment participated in semi-structured telephone interviews. Participants were selected through purposive sampling until meaning saturation was achieved, defined as the point at which no new experiential themes emerged. Interviews were transcribed verbatim and analyzed using a hybrid deductive-inductive thematic analysis guided by the Felce and Perry quality-of-life framework, supported by ATLAS.ti v24. Results: Patients described AMD as a condition strongly associated with fear, uncertainty, and emotional distress, particularly related to progressive visual loss and blindness. Intravitreal injections were initially perceived as invasive and anxiety-provoking; however, over time many participants associated treatment with hope, visual stability, and preservation of independence. Family support, religious beliefs, and trust in the treating ophthalmologist emerged as important factors for emotional coping and treatment adherence. Participants also reported subjective improvement in daily activities such as reading, mobility, self-care, and social interaction. Nevertheless, some continued to experience limitations related to transportation, dependence on others, and social isolation. Concerns about continuity of care and access to medication were frequently expressed. Conclusion: Quality of life in patients with AMD receiving anti-VEGF therapy extends beyond visual outcomes alone and is deeply influenced by emotional, social, and functional factors. Although treatment generated fear and discomfort at the beginning, it also represented an opportunity to maintain autonomy and social participation. These findings highlight the importance of patient-centered care strategies that integrate psychosocial support, clear communication, and continuous access to treatment.

Indexed as

activities of daily livingintravitreal injectionsmedication adherencevision disorders

Identifiers

PMID42733609
PMCPMC13571611

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.